Navigation Links
Imprimis Names Two Experts To Its Science And Regulatory Board
Date:9/10/2012

SOLANA BEACH, Calif., Sept. 10, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. today announced the appointment of two new members of its Science and Regulatory Advisory Board - Drs. Lee S. Simon and Allan Green, who both have extensive experience in the pharmaceutical industry, particularly with regard to the U.S. Food and Drug Administration's approval process.

Simon and Green will join Dr. Gerald Yakatan on the advisory board, whose first task will be to provide advice and guidance as Imprimis conducts Phase 3 clinical trials of its topical analgesic and anti-inflammatory drug, Impracor. Additionally, the Imprimis Science and Regulatory Advisory Board will work closely with Company management as Imprimis moves forward with the development of its patented Accudel topical drug delivery platform for other drug development products.

"We welcome the arrival of Dr. Lee Simon and Dr. Allan Green to our Science and Regulatory Advisory Board. As members of this important arm of the Company, they will provide invaluable insights and guidance throughout the process of FDA approval, from the design and management of clinical trials to the communication, organization and submission of data. We intend to leave no stone unturned as we navigate the approval process and communicate with our counterparts at the FDA. These two gentlemen, along with Dr. Yakatan, will help us reach our goals of approval of Impracor and as well as future submissions," said Mark L. Baum, CEO of Imprimis Pharmaceuticals.

Simon has served as the FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products, and on multiple FDA advisory committees. He has extensive experience in drug development as a senior investigator for celecoxib in the U.S. Simon was a senior consultant to Pharmacia/Searle on COX-2 development and has served on consulting advisory boards for numerous other pharmaceutical companies. Simon is on the editorial boards of multiple journals and has authored more than 110 original publications, reviews and book chapters, and has edited several text books.

Green is a physician, attorney, and research scientist who has significant operating management experience with a number of successful biomedical companies. Dr. Green has provided counsel to companies, hospitals and medical research foundations and has served as a technical consultant to  government committees. He has successfully represented many American and non-U.S. clients in their relationships with the FDA and has organized a number of multi-disciplinary conferences on healthcare, pharmaceutical and funding issues. He has held several medical school appointments and currently is Adjunct Professor at Boston College Law School, where he teaches food and drug law.

Both Simon and Green are principals with Cambridge, MA-based SDG, LLC, which provides FDA regulatory expertise, advice on clinical study design and data interpretation  and strategic planning for FDA-regulated industry.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. The Imprimis Pharmaceuticals, Inc. website is currently under construction and is expected to launch in September 2012.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Mark L. Baum
(858) 433-2800


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
2. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
3. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
4. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
5. BioMotiv Names New Chief Executive Officer
6. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
7. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
8. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
9. Casteel Schoenborn Names Wilson Grabill Of Counsel for Life Sciences Communications
10. Zimmer Holdings Names Christopher Begley to Board of Directors
11. BioSurplus Names Dawn Hocevar Director, National Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... WASHINGTON D.C. , May 4, 2016 /PRNewswire/ ... its member companies concluded a series of free ... training in global requirements for Good ... part of quality assurance which ensures that products are ... by the marketing authorization (MA) or product specification. Only ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... NEW YORK (PRWEB) , ... May 05, 2016 , ... ... and swimming safety – today announced a new partnership to reach nearly 1 million ... can happen in an instant and is the leading cause of accidental death in ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun ... talk highlighting the organization’s successful Care Transitions program at the 9th ... was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” ...
(Date:5/5/2016)... ... , ... The 2016 Nike Soccer Camp will be directed by the 2015 ... Together they bring their winning Vandals coaching philosophy to young athletes. Programs are offered ... high school players. Session dates are as follows: , Youth Day Camp – July ...
(Date:5/5/2016)... ... May 05, 2016 , ... Talent Tech Labs (TTL) is pleased ... of National Nurses Week (May 6-12). Currently, HireNurses is a job listing ... into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality ...
Breaking Medicine News(10 mins):